Global law firm Norton Rose Fulbright has enhanced its intellectual property disputes team with the addition of Sanya Sukduang and Jon Davies as partners in its Washington, DC office. Joining from Cooley, their arrival augments the firm’s life sciences IP services, adding deep experience in pharmaceutical and biotechnology patent disputes at a time of increasing market demand.
The move reflects Norton Rose Fulbright’s continued investment in intellectual property as a core strategic practice, responding to the growing complexity of IP-related challenges that demand coordinated strategies across jurisdictions. Sanya and Jon bring established strength in all areas of life sciences disputes, including Hatch-Waxman, BPCIA, trade secret and competitor v. competitor patent litigation, further complementing the firm’s capabilities across patent prosecution, antitrust, regulatory and broader litigation work in the life sciences sector.
“Sanya and Jon are highly regarded for advising clients in pharmaceutical and biotechnology patent disputes, and their arrival underscores our commitment to being leaders in intellectual property law and the life sciences sector,” said Jeff Cody, Norton Rose Fulbright’s Global and US Managing Partner. “Their practices complement the firm’s cross-border capabilities in pharmaceutical litigation, particularly between the US and Canada.”
Sanya brings more than two decades of experience litigating life sciences patent disputes, with a focus on representing brand pharmaceutical companies in Hatch-Waxman litigation, biologics disputes, life science trade secret litigation and medical device matters. His practice also includes advising clients on pre-litigation strategy, due diligence and patent portfolio planning, with extensive experience before federal district courts and the US Court of Appeals for the Federal Circuit.
Jon focuses his practice on pharmaceutical and biotechnology patent litigation, including Hatch-Waxman and matters under the Biologics Price Competition and Innovation Act. He holds a PhD in molecular genetics and brings scientific depth to complex patent disputes involving small-molecule drugs and biologics. His experience spans all phases of district court litigation, Federal Circuit appeals and related pre-litigation counseling.
“The state of life sciences disputes is evolving rapidly, with these cases often involving multiple challengers, compressed timelines and heightened commercial risk,” Tim Kenny, Norton Rose Fulbright’s US Head of Intellectual Property, commented. “Sanya and Jon amplify our ability to guide clients through the full lifecycle of these matters, from early-stage strategic counseling through trial and appeal. They also bring pharmaceutical experience that aligns with the firm’s IP, litigation and regulatory offering.”